Disseminated intravascular coagulation
Authors:
Top Cited Papers
Open Access
- 6 June 2025
- journal article
- review article
- Published by Springer Nature in Journal of Intensive Care
- Vol. 13 (1) , 1-24
Abstract
Background: Disseminated intravascular coagulation (DIC) is characterized by systemic coagulation activation, anticoagulation pathway impairment, and persistent fibrinolysis suppression, resulting in widespread microvascular thrombosis, followed by hemorrhagic consumption coagulopathy and multiple organ dysfunction syndrome. This article aimed to provide a comprehensive and updated DIC overview. Main body: The International Society on Thrombosis and Hemostasis provides definitions, underlying disorders, diagnostic algorithms, and management guidelines for DIC. Two clinical features of DIC are hemorrhagic consumption coagulopathy, characterized by oozing and difficult-to-control bleeding, and microvascular thrombosis, leading to dysfunctions in multiple vital organs. Histones derived from cellular damage play central roles in the innate-immune-based coagulation model, comprising the initiation, amplification, propagation, and reinforcement phases, which, if dysregulated, develop into DIC. Thus, the innate immune-mediated pathogenic pathways in DIC have become clear. Cell death, damage-associated molecular patterns (including histones), crosstalk between hypoxic inflammation and coagulation, and the serine protease network (comprising coagulation and fibrinolysis, the Kallikrein–Kinin system, and complement pathways) play major roles in DIC pathogenesis. Conversely, these pathogenic pathways and DIC synergistically contribute to organ dysfunction, leading to poor prognoses. Effective DIC management requires treating the underlying condition, along with substitution therapies and, in some cases, antifibrinolytics. Anticoagulant use has been extensively debated; however, the selection of optimal target patients could optimize their application and improve patient outcomes in the near future. Conclusions: This review provides an updated overview of DIC, aiming to help readers understand various aspects of DIC today.Keywords
Funding Information
- JSPS KAKENHI (23K08455)
This publication has 221 references indexed in Scilit:
- The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024Acute Medicine & Surgery, 2025
- Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated CoagulopathyJAMA, 2019
- Location is the key to function: HMGB1 in sepsis and trauma-induced inflammationJournal of Leukocyte Biology, 2019
- Polyphosphate in thrombosis, hemostasis, and inflammationResearch and Practice in Thrombosis and Haemostasis, 2018
- A novel “complement–metabolism–inflammasome axis” as a key regulator of immune cell effector functionEuropean Journal of Immunology, 2016
- Promotion of Hypercoagulability in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis by C5a‐Induced Tissue Factor–Expressing Microparticles and Neutrophil Extracellular TrapsArthritis & Rheumatology, 2015
- Damage‐associated molecular pattern–activated neutrophil extracellular trap exacerbates sterile inflammatory liver injuryHepatology, 2015
- Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe SepsisJAMA, 2003
- High-Dose Antithrombin III in Severe SepsisJAMA, 2001
- Microthrombosis in injured and burned patientsThe Journal of Pathology and Bacteriology, 1967